Get In The Know About
Your Fertility

The Fertility LifeLines™ In The Know series was designed to provide patients with free resources to help them along their paths to parenthood. In The Know: What No One Tells You About Fertility provides compelling and relevant information to women, men and couples about their fertility health concerns. In The Know: What No One Tells You About Male Fertility was developed to address the male factors of infertility.

To receive free copies of these booklets, register now with Fertility LifeLines™. Current members can order free copies by calling the hotline at 1-866-LETS-TRY (1-866-538-7879). All calls are free and confidential.

In The Know The In The Know: What No One Tells You About Fertility booklet covers the broad range of issues that couples face when struggling with infertility, including a description of infertility in males and females, how to cope with the emotional stresses of infertility, an overview of the treatments that are
available, and resources that can provide couples with information to
navigate the costs of treatment. Alice D. Domar, Ph.D., a well-known fertility expert and the “Fertility Goddess” according to Vogue, wrote the foreword to the original In The Know booklet.

The In The Know booklet was created to address the gap in the current resources available to couples seeking information about infertility, which were uncovered in a survey cosponsored by Fertility LifeLines™ and Conceive Magazine. The survey found that only about half of the women who responded felt the available information on infertility is sufficient; of the remainder:

  • 23% felt there wasn't enough information on emotional issues
  • 22% needed additional information on dealing with stress
  • 22% wanted more male-oriented information

In The KnowIn The Know: What No One Tells You About Male Fertility, the newest addition to the series, was developed to address the need for resources targeted specifically toward men affected by infertility. During a recent survey cosponsored by Fertility LifeLines™ and Men’s Health Network, 83% of men reported that they would be equally or more active than their partner in seeking information about infertility, if they were struggling to conceive. Additional key findings include:

  • 28% of the men surveyed reported feeling embarrassed when dealing with fertility issues and 39% reported feeling sad or depressed
  • Nearly half (45%) of the men surveyed would wait more than a year to seek medical attention after struggling to conceive with their partner, although most of the men surveyed (84%) agreed that infertility is a significant medical condition and 69% think that it is very common

Click here for more survey results.

To receive a free copy of the In The Know: What No One Tells You About Male Fertility booklet, register now with Fertility LifeLines™. Current members can order a free copy by calling the hotline at 1-866-LETS-TRY (1-866-538-7879). All calls are free and confidential.

“With current medical advances in fertility treatments, women are having more success getting pregnant today than they were just 10 years ago,” said Dr. Dormar. “Unfortunately, women are waiting longer than necessary to seek medical help because they are concerned with both the emotional and financial impact of treatment. The In The Know booklet is a great resource for these women.”

FIND A FERTILITY SPECIALIST

Enter your Zip code to find a fertility treatment specialist or fertility clinic in your area:

Important Considerations:
Gonal-f® RFF Pen (follitropin alfa injection) is indicated for the induction of ovulation and pregnancy in the oligo-anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure. Gonal-f® RFF Pen is also indicated for the development of multiple follicles in the ovulatory patient participating in an Assisted Reproductive Technology (ART) program. Gonal-f® RFF Pen (follitropin alfa injection) should only be prescribed by physicians specializing in fertility or reproductive health. Gonal-f® is a potent gonadotropic substance capable of causing mild to severe adverse reactions, including Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications, and multiple births. Gonal-f® is contraindicated in women who exhibit prior hypersensitivity to FSH preparations, primary gonadal failure, uncontrolled thyroid or adrenal dysfunction and pregnancy. Nursing women should not use Gonal-f®. Common side effects include headache, abdominal pain, enlarged abdomen, and injection site disorders. For complete product details, see full prescribing information.

Important Considerations:
Women: Gonal-f® (follitropin alfa for injection) is indicated for the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure. Gonal-f® is also indicated for the development of multiple follicles in the ovulatory patient participating in an Assisted Reproductive Technology (ART) program.
Men: Gonal-f® (follitropin alfa for injection) is indicated for the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure. Gonal-f® (follitropin alfa for injection) should only be prescribed by physicians who are thoroughly familiar with infertility problems and their management. Gonal-f® is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary or vascular complications. Gonal-f® is contraindicated in women and men who exhibit prior hypersensitivity to recombinant FSH preparations or one of their excipients, high levels of FSH indicating primary gonadal failure, uncontrolled thyroid or adrenal dysfunction, sex hormone dependent tumors of the reproductive tract and accessory organs, and an organic intracranial lesion such as a pituitary tumor; and in women who exhibit abnormal uterine bleeding of undetermined origin, ovarian cyst or enlargement of undetermined origin and pregnancy. Women who are pregnant or nursing should not use Gonal-f®. The most common side effects in patients using Gonal-f® include headache, ovarian cysts, nausea and upper respiratory infections in women and in men, acne, breast pain and growth, and fatigue. Injection site reactions were also reported. Reports of multiple births have been associated with Gonal-f® treatment. For complete product details, see the full prescribing information.

For complete product details, please read the Prescribing Information offered below.


© EMD Serono, Inc. CIM Last Update 2008-09-16
This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

This site contains information that is intended for US residents only. Canadian residents should consult the EMD Serono Canada Inc. Web site at www.emdserono.ca for information on products and services approved in Canada.

EMD Serono

Close

Please wait... loading

View the Full Glossary